ArticleEBioMedicine2022
Impacts of neoadjuvant chemoradiotherapy on the immune landscape of esophageal squamous cell carcinoma.
Article in EBioMedicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06478264 (Efficacy and Safety of Adebrelimab Combined With Chemoradiotherapy in the Treatment of Esophageal Small Cell Carcinoma), which is not on this map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Efficacy and Safety of Adebrelimab Combined With Chemoradiotherapy in the Treatment of Esophageal Small Cell Carcinoma: a Single-arm, Multicenter, Phase II Clinical Study
Who cites it
20 citing papers in PubMed, 35 citations in OpenAlex.
- Preoperative pembrolizumab (anti-PD-1 antibody) combined with chemoradiotherapy for esophageal squamous cell carcinoma: a phase 1/2 trial (PALACE-2).Signal transduction and targeted therapy · 2025Trial
- Induction Therapy of Tislelizumab Combined with Cisplatin and 5-Fluorouracil and Subsequent Conversion Surgery in Patients with Unresectable Advanced Esophageal Squamous Cell Carcinoma: A Phase 2, Single Center Study.Annals of surgical oncology · 2024Trial
- NF-κB-active tumors with matrix CAFs and suppressive immunity as key resistance mechanisms to chemoradiation in rectal cancer.Experimental & molecular medicine · 2026Article
- Gastric bacterial microbiota and gastric carcinogenesis: from dysbiosis to immune remodeling and therapeutic opportunities.Frontiers in immunology · 2026Review
- Single-cell insights into tumor microenvironment heterogeneity and plasticity: transforming precision therapy in gastrointestinal cancers.Journal of experimental & clinical cancer research : CR · 2025Review
- Proteomics analysis and immune profiling reveal regulators of PD-L1 in oesophageal squamous cell carcinoma.British journal of cancer · 2025Article
- Progress in the Application of Single-Cell Sequencing in Neoadjuvant Therapy for Esophageal Cancer.Cureus · 2025Review
- Immune checkpoint inhibitors in the first-line treatment of esophageal squamous cell carcinoma: Minireview for a big shift.World journal of gastrointestinal oncology · 2025Review
- CMTM4 promotes the motility of colon cancer cells under radiation and is associated with an unfavorable neoadjuvant chemoradiotherapy response and patient survival in rectal cancer.Oncology letters · 2025Article
- Deciphering the generation of heterogeneity in esophageal squamous cell carcinoma metastasis via single-cell multiomics analysis.Journal of translational medicine · 2025Article
- Predicting Postoperative Pneumonia in ESCC After Neoadjuvant Chemo-Immunotherapy: Combined Use of ARISCAT Score and Inflammatory Biomarkers.Journal of inflammation research · 2025Article
- KDM1A epigenetically enhances RAD51 expression to suppress the STING-associated anti-tumor immunity in esophageal squamous cell carcinoma.Cell death & disease · 2024Article
- Tumor microenvironment remodeling after neoadjuvant chemoradiotherapy in local advanced rectal cancer revealed by single-cell RNA sequencing.Journal of translational medicine · 2024Article
- Definitive chemoradiotherapy induces T-cell-inflamed tumor microenvironment in unresectable locally advanced esophageal squamous cell carcinoma.Journal of gastroenterology · 2024Article
- Article
- Cathepsin L promotes oesophageal squamous cell carcinoma development and may be associated with tumour-associated macrophages.Heliyon · 2024Article
- Single-cell profiling of response to neoadjuvant chemo-immunotherapy in surgically resectable esophageal squamous cell carcinoma.Genome medicine · 2024Article
- Immunological biomarkers and predictive model for recurrence of esophageal squamous cell carcinoma after combined immunotherapy and neoadjuvant chemotherapy.American journal of cancer research · 2024Article
- Deciphering tumor-infiltrating dendritic cells in the single-cell era.Experimental hematology & oncology · 2023Review
- Characterization of the tumor microenvironment by single-cell RNA sequencing in non-small cell lung cancer treated with neo-adjuvant immunotherapy.Translational lung cancer research · 2023Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
16 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNeoadjuvant chemoradiotherapy (neoCRT) followed by surgery is the most common approach for locally advanced resectable esophageal squamous cell carcinoma (ESCC) patients. How neoCRT impacts ESCC tumor immune microenvironment (TIME) has not been fully understood.
methodsSingle-cell RNA sequencing (scRNA-seq) was conducted to examine the neoCRT-driven cellular and molecular dynamics in 8 pre- and 7 post-neoCRT ESCC samples from 8 male patients.
findingsscRNA-seq data of about 112,000 cells were obtained. Expression programs of cell cycle, epithelium development, immune response, and extracellular structure in pre-treatment tumor cells were related to neoCRT response. Spearman correlation between CD8
interpretationOur comprehensive picture of the neoCRT-related immune changes provides deeper insights into immunological mechanisms associated with ESCC response to neoCRT, which may aid in future development of immune-strategies for improving ESCC treatment.
fundingThis work was supported by the National Natural Science Foundation of China (82072607).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.